LSE-AIM$MXCT

Maxcyte Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

MaxCyte's first quarter results were announced, showing a decrease in revenue compared to the same period last year, but the company is pleased with progress on strategic initiatives and updated 2023 revenue guidance.

MaxCyte reported a 26% decrease in total revenue for Q1 2023, amounting to $8.6 million, compared to $11.6 million in Q1 2022. Despite the revenue decline, the company highlighted the addition of two new SPL partnerships and progress towards potential commercial approval of a product enabled by their platform.

  • Total revenue for Q1 2023 was $8.6 million, a 26% decrease compared to Q1 2022.
  • Core business revenue was $7.8 million, a 19% decrease compared to Q1 2022.
  • Two SPL partnerships were signed year-to-date, bringing the total number of SPL partners to 20.
  • Total cash, cash equivalents, and short-term investments were $224.7 million as of March 31, 2023.

Headline financials

Total Revenue

$8.58M

Previous: $11.6M-26.0%
EPS (adj)

-$0.11

Previous: -$0.04-175.0%
Capital Expenditures

$1.56M

Previous: $6M-74.0%
Free Cash Flow

-$5.88M

Previous: -$9.69M+39.3%
Net Income

-$10.9M

Previous: -$4.07M-167.5%
Operating Income

-$13.2M

Previous: -$4.16M-216.8%
Gross Profit

$7.58M

Previous: $10.5M-28.0%
Cash & Equivalents

$37.8M

Previous: $240M-84.2%
Total Assets

$282M

Previous: $291M-3.2%
Stock-Based Comp

$3.28M

Previous: $2.46M+33.1%

Revenue & EPS history

Maxcyte · Revenue · Quarterly

$8.58M

Q1 2023-26%vs Q1 2022
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Revenue by segment

Maxcyte · $804K total across 1 segment · Q1 2023

  • Program-Related
    $804K-59.9%

Forward guidance

MaxCyte expects total revenue for 2023 to grow between 8% and 12% compared to 2022, with core revenue growth of 5% to 10%. SPL program-related revenue expectations remain at approximately $6 million for the year.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+291.3%

Avg return

Earnings day

-2.8%

Avg return

5 days after

+220.5%

Avg return

30 days after

42%

10 / 24 earnings

Positive

+7042.3%

Q1 2025

Best reaction

-29.9%

Q2 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+24.1%+29.0%
Q3 2025-12.0%-7.2%-12.0%
Q2 2025-29.9%-37.7%-30.9%
Q1 2025+7042.3%-19.7%-21.5%
Q4 2024-8.4%-6.1%+5251.6%
Q3 2024+0.5%-7.3%-6.7%
Q2 2024+2.5%-3.7%-8.8%
Q1 2024+0.5%+21.2%+23.5%
Q4 2023+0.3%+8.6%+4.0%
Q3 2023-1.5%+2.4%+42.6%
Q2 2023-2.7%-14.3%-17.4%
Q1 2023-0.6%-19.2%-2.8%
Q4 2022+2.7%+2.4%+30.8%
Q3 2022-9.4%+3.0%-19.9%
Q2 2022+3.6%+4.9%+16.4%
Q1 2022-4.3%-13.0%-12.9%
Q1 2021-4.3%-13.0%-12.9%
Q4 2021+3.4%+6.7%-23.7%
Q4 2019+3.4%+6.7%-23.7%
Q3 2020-7.7%+3.8%-9.7%
Q3 2021-7.7%+3.8%-9.7%
Q4 2020-4.1%-6.2%-26.3%
Q2 2021-0.3%-6.5%-29.4%
Q2 2020-0.3%-6.5%-29.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro